Elevance Health (ELV) Projected to Post Earnings on Wednesday

Key Points

• Q1 2026 earnings due before market open on Apr 22: Analysts expect $10.74 EPS and ~$48.214B revenue for the quarter, and Elevance has set FY 2026 guidance at 25.50 EPS.
• In the last reported quarter (Jan. 28) Elevance posted $3.33 EPS (beating estimates) and $49.31B revenue, with revenue up 9.6% year-over-year; analysts project about $34 EPS for the current fiscal year and $39 next year.
• Shares trade around $313 with a market cap of $68.85B and a P/E of 12.48; the company raised its quarterly dividend to $1.72 ($6.88 annual, ~2.2% yield) and the Street consensus rating is a "Hold" with a $384.67 average price target.

Elevance Health (NYSE:ELV - Get Free Report) is projected to post its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect Elevance Health to post earnings of $10.74 per share and revenue of $48.2140 billion for the quarter. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 8:30 AM ET.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analysts' expectations of $49.52 billion. During the same quarter in the previous year, the firm posted $3.84 earnings per share. The company's revenue was up 9.6% compared to the same quarter last year. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.

Elevance Health Trading Down 0.8%

Shares of NYSE ELV opened at $313.44 on Wednesday. The stock's 50 day moving average price is $310.23 and its two-hundred day moving average price is $332.09. Elevance Health has a 52-week low of $273.71 and a 52-week high of $441.47. The stock has a market capitalization of $68.85 billion, a P/E ratio of 12.48, a PEG ratio of 1.74 and a beta of 0.49. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were issued a $1.72 dividend. This is a positive change from Elevance Health's previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.2%. Elevance Health's dividend payout ratio is currently 27.39%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ELV shares. Jefferies Financial Group decreased their price objective on Elevance Health from $401.00 to $395.00 and set a "buy" rating for the company in a report on Friday, January 30th. Truist Financial decreased their price target on Elevance Health from $390.00 to $375.00 and set a "buy" rating for the company in a research note on Monday. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $332.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Mizuho decreased their price target on Elevance Health from $413.00 to $350.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Finally, Evercore initiated coverage on Elevance Health in a research note on Wednesday, April 8th. They set a "hold" rating and a $345.00 price target for the company. Twelve investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $384.67.

Institutional Trading of Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of ELV. Wellington Management Group LLP increased its position in Elevance Health by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company's stock worth $2,906,051,000 after buying an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Elevance Health by 27.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company's stock worth $2,610,261,000 after buying an additional 1,607,274 shares during the last quarter. Baupost Group LLC MA increased its position in Elevance Health by 114.1% during the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company's stock worth $426,195,000 after buying an additional 703,000 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its position in Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company's stock worth $660,935,000 after buying an additional 627,038 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Elevance Health by 216.3% in the third quarter. AQR Capital Management LLC now owns 801,268 shares of the company's stock valued at $258,689,000 after purchasing an additional 547,950 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.